Interní Med. 2017; 19(3): 126-130 | DOI: 10.36290/int.2017.023

Different aspects of treatment of stable COPD according to GOLD 2017 strategy

MUDr. Ondřej Kudela, MUDr. Vratislav Sedlák, Ph.D., MUDr. Vladimír Koblížek, Ph.D.
Plicní klinika FN Hradec Králové, LF HK UK v Praze

This article examines changes in therapeutic strategies in stable COPD, as presented in The Global Initiative For Chronic Obstructive

Pulmonary Disease(GOLD) 2017 revised document.

Keywords: COPD, treatment, recommendations, phenotype

Published: July 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kudela O, Sedlák V, Koblížek V. Different aspects of treatment of stable COPD according to GOLD 2017 strategy. Interní Med. 2017;19(3):126-130. doi: 10.36290/int.2017.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Global Initiative for Chronic Obstructive Lung Disease, Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2011), http://goldcopd.org.
    2. Global Initiative for Chronic Obstructive Lung Disease, Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease 2017 Report, dostupné z: http://goldcopd.org.
    3. Koblížek V, et al.: Doporučený postup ČPFS pro diagnostiku a léčbu stabilní CHOPN, dostupné z: www.pneumologie.cz.
    4. Miravitlles M. Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD, Arch Bronconeumol 2012; 48: 247-257 - Vol. 48 Num.7 DOI: 10.1016/j.arbr.2012.05.00. Go to original source...
    5. Hurst J. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease, N Engl J Med 2010; 363: 1128-1138, September 16, 2010, DOI: 10.1056/NEJMoa0909883. Go to original source... Go to PubMed...
    6. Global Initiative for Astma, Global Initiative for Chronic Obstructive Lung Disease, Diagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS), dostupné z: http://ginasthma.org.
    7. Augusti A. Clinical and prognostic heterogeneity of C and D GOLD groups, Eur Respir J 2015; 46: 250-254 | DOI: 10.1183/09031936.00012215. Go to original source... Go to PubMed...
    8. Lange P. Prediction of the Clinical Course of Chronic Obstructive Pulmonary Disease, Using the New GOLD Classification A Study of the General Population, Am J Respir Crit Care Med 2012. Go to original source... Go to PubMed...
    9. Zatloukal J. Komentář k nové strategii GOLD 2017, Studia pneumologica et phthiseologica, vol. 76, 01/2017, v tisku.
    10. Jones P. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification, European Respiratory Journal 2013; 42: 647-654; DOI: 10.1183/09031936.00125612. Go to original source... Go to PubMed...
    11. Han MK. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy, Am J Respir Crit Care Med., 2014; 189(12): 1503-1508. Go to original source... Go to PubMed...
    12. Albert RK. Azithromycin for prevention of exacerbations of COPD, N Engl J Med., 2011; 365(8): 689-698. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.